Latest research

Fewer than 13% of people in England eligible for Sativex can access it, according to a new report published today. People living in Wales, Scotland and Northern Ireland also face difficulties.

This study took an in-depth look at the dating experiences of a small group of people living with MS.

The MS Trust is delighted that Kesimpta (ofatumumab) has been approved by SMC for people with active relapsing remitting multiple sclerosis.

Difficulties accessing NHS stem cell transplants (also known as HSCT or AHSCT) for multiple sclerosis were highlighted in national newspapers this weekend.

Researchers have investigated how the risk of developing long term disability has changed over the last three decades for people whose MS begins in childhood.

The number of people being diagnosed with multiple sclerosis around the world is increasing. In this article we take a look at recent research which investigates who might be more succeptible to multiple sclerosis and why that might be. 

The MS Trust is very disappointed that NICE is unable to recommend ozanimod as an NHS treatment for relapsing remitting MS in England and Wales.

Researchers have identified three new MRI-based subtypes are better able to predict MS activity, disability progression and treatment response than the standard relapsing and progressive subtypes.

The MS Trust is delighted that ofatumumab (Kesimpta) has been approved by NICE for people with active relapsing remitting multiple sclerosis.

Under-the-skin (subcutaneous) injection of Tysabri (natalizumab) has been approved for UK and Ireland.

The MHRA has granted marketing authorisation for ofatumumab (Kesimpta) for active relapsing remitting MS.

Researchers have investigated how long it takes for disease modifying drugs to be fully effective at reducing relapses and slowing progression.